Identification and Treatment of the Liability to Develop Schizophrenia
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This study seeks to determine whether adult, non-psychotic, first-degree relatives of
schizophrenic patients who show specific neurocognitive deficits and negative symptoms will
show improvements in these areas following a 6-month, double-blind trial of a low dose (up to
2.0 mg) of risperidone.